Manifestation of the JLab proton polarization data on the behaviour of strange nucleon form factors

Special eight-resonance unitary and analytic model of nucleon electromagnetic structure is used to analyze, first the classical proton form factor data obtained by the Rosenbluth technique and then also the contradicting JLab proton polarization data on the ratio $\mu_p G_{Ep}(Q^2)/G_{Mp}(Q^2)$ with the aim to investigate a manifestation of the latter on the strange nucleon form factors behaviour.Comment: Latex, 9 pages, 3 figures. Talk given at the PAVI06 International Workshop, 16-20 May, 2006, Milos, Greec

Synthesis of sulfoximine propargyl carbamates under improved conditions for rhodium catalyzed carbamate transfer to sulfoxides

Sulfoximines provide aza-analogues of sulfones, with potentially improved properties for medicinal chemistry. The sulfoximine nitrogen also provides an additional vector for the inclusion of other functionality. Here, we report improved conditions for rhodium catalyzed synthesis of sulfoximine (and sulfilimine) carbamates, especially for previously low-yielding carbamates containing pi-functionality. Notably we report the preparation of propargyl sulfoximine carbamates to provide an alkyne as a potential click handle. Using Rh2(esp)2 as catalyst and a DOE optimization approach provided considerably increased yields

M\u27mmm, Branding: Marketing, Music, and Merchandise

Panel Chair: Lisa Roy-Davis Papers Presented: Personality or “Impersonality”? A Case Study of a Niche Luxury Brand’s Online Emotional Branding Strategies by Maiojian Zheng Confront the Ethical Issue: The Luxury Industry\u27s Lack of Transparency An Ethical Ad Campaign of Maison Marton Margiela by Maiojian Zheng The Future of the Fashion Industry by Paul Z. Armstrong Beauty Standards: An Historical Exploration by Hannah Neeley The 1950s: American Fashion at Midcentury by Emily Keen

New Precision Limit on the Strange Vector Form Factors of the Proton

The parity-violating cross-section asymmetry in the elastic scattering of polarized electrons from unpolarized protons has been measured at a four-momentum transfer squared Q(2) = 0.624 GeV2 and beam energy E-b = 3.48 GeV to be A(PV) = -23.80 +/- 0.78(stat) +/- 0.36(syst) parts per million. This result is consistent with zero contribution of strange quarks to the combination of electric and magnetic form factors G(E)(s) + 0.517G(M)(s) = 0.003 +/- 0.010(stat) +/- 0.004(syst) +/- 0.009(ff), where the third error is due to the limits of precision on the electromagnetic form factors and radiative corrections. With this measurement, the world data on strange contributions to nucleon form factors are seen to be consistent with zero and not more than a few percent of the proton form factors

Feasibility study of Glucagon-like peptide-1 analogues for the optimization of Outcomes in obese patients undergoing AbLation for Atrial Fibrillation (GOAL-AF) protocol

BackgroundCatheter ablation for atrial fibrillation is recommended for symptomatic patients after failed medical therapy. Ablation has a higher failure rate in obese patients, and both the prevalence of atrial fibrillation and obesity are increasingly globally. The outcome of ablation can be improved if obese patients can achieve goal-oriented weight reduction prior to ablation. Conventional weight loss strategies, however, can be difficult to access and can delay ablation, thereby risking a lower chance of maintaining sinus rhythm. Effective weight-loss medications, such as the glucagon-like peptide inhibitor-1 drugs, offer the potential for incremental impact on weight loss over a shorter period of time as a bridging therapy. The aim of this study is to assess the feasibility of using liraglutide, a glucagon-like peptide inhibitor-1, in producing weight loss in obese patients before catheter ablation.MethodsThe study is an open-label, uncontrolled, prospective single-centre feasibility study of daily liraglutide injections in the treatment of obese patients for at least 13 weeks before and 52 weeks after AF ablation. Adult patients with symptomatic AF whose body mass index ≥ 30 will be recruited from those planning to undergo ablation. Feasibility will be determined based on the recruitment rate, adherence to the medication, and the amount of weight loss achieved over the study period. Exploratory outcomes include changes in atrial structure, function, and fibrosis with weight loss evaluated by cardiac magnetic resonance imaging, electroanatomic mapping, and patient-reported outcome measure.DiscussionThis study will allow us to determine whether the use of liraglutide in obese patients with atrial fibrillation undergoing ablation is feasible with adequate recruitment. The additional information on adherence and average weight loss over the study period will inform the design of a future definitive randomized controlled trial.Trial registrationClinicalTrials.gov (NCT05221229). Registered on 2 February 2022.Trial fundingMetchley Park Medical Society and University of Birmingham Starter Fellowship, British Heart Foundation Accelerator Grant, Abbott Investigator-Initiated Study Grant